Nuevolution A/S is a unique drug discovery company poised to revolutionize drug discovery by utilising its proprietary Chemetics®  technology to synthesize and identify many 100's of drug leads to most therapeutically relevant targets in a few weeks.

Chemetics® represents the ultimate “convergent” drug discovery technology. It is a unique, patent protected hybrid of proven wet chemistry and molecular biology that enables the rapid synthesis and selection of potentially millions to billions of drug-like compounds in a single test tube.

By applying Chemetics® to recognised disease targets, Nuevolution has identified novel, drug-like, small molecules with the potential to address major unmet medical needs within the cardiovascular area and other important disease areas.

The Nuevolution team comprises a 28 strong group of world class scientists and business . The company was founded in May 2001 and is headquartered in Copenhagen, Denmark, in the heart of the biotech cluster Medicon Valley, comprising the Greater Copenhagen area and Southern Sweden.

To date, Nuevolution has raised € 29 million in venture capital based on the ongoing development of its proprietary Chemetics® technology. Investors include Novo A/S, Scandinavian Life Science Venture (SLS Venture), SEB Företagsinvest and Vaekstfonden.